Stock Track | ADMA Biologics Soars 5.20% Intraday on $125 Million Share Repurchase Announcement with JPMorgan

Stock Track03-02

ADMA Biologics' stock surged 5.20% during intraday trading on Monday, following the company's announcement of a significant capital return initiative.

The biopharmaceutical company revealed a planned $200 million share repurchase program for 2026, including a $125 million accelerated share repurchase agreement with JPMorgan. This initiative is part of the company's existing program authorizing up to $500 million in repurchases.

ADMA's President and CEO Adam Grossman stated that the company views its common stock as "meaningfully undervalued" and represents "the most compelling near-term capital deployment opportunity." The announcement reflects management's confidence in ADMA's strong financial position, durable free cash flow profile, and long-term growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125901366?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 22:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125901366","market":"nz","top_or_hot":-1,"title":"Stock Track | ADMA Biologics Soars 5.20% Intraday on $125 Million Share Repurchase Announcement with JPMorgan","media":"Stock Track","content":"<p>ADMA Biologics' stock surged 5.20% during intraday trading on Monday, following the company's announcement of a significant capital return initiative.</p><p>The biopharmaceutical company revealed a planned $200 million share repurchase program for 2026, including a $125 million accelerated share repurchase agreement with JPMorgan. This initiative is part of the company's existing program authorizing up to $500 million in repurchases.</p><p>ADMA's President and CEO Adam Grossman stated that the company views its common stock as \"meaningfully undervalued\" and represents \"the most compelling near-term capital deployment opportunity.\" The announcement reflects management's confidence in ADMA's strong financial position, durable free cash flow profile, and long-term growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ADMA Biologics Soars 5.20% Intraday on $125 Million Share Repurchase Announcement with JPMorgan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ADMA Biologics Soars 5.20% Intraday on $125 Million Share Repurchase Announcement with JPMorgan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-02 22:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ADMA Biologics' stock surged 5.20% during intraday trading on Monday, following the company's announcement of a significant capital return initiative.</p><p>The biopharmaceutical company revealed a planned $200 million share repurchase program for 2026, including a $125 million accelerated share repurchase agreement with JPMorgan. This initiative is part of the company's existing program authorizing up to $500 million in repurchases.</p><p>ADMA's President and CEO Adam Grossman stated that the company views its common stock as \"meaningfully undervalued\" and represents \"the most compelling near-term capital deployment opportunity.\" The announcement reflects management's confidence in ADMA's strong financial position, durable free cash flow profile, and long-term growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADMA","symbol_name":"ADMA Biologics Inc","start_time":0,"source_url":"","article_id":"1125901366","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125901366","pubTimestamp":1772462580,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ADMA Biologics' stock surged 5.20% during intraday trading on Monday, following the company's announcement of a significant capital return initiative.The biopharmaceutical company revealed a planned...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADMA":"ADMA Biologics Inc"},"translate_title":"个股追踪|ADMA Biologics盘中大涨5.20%与摩根大通宣布回购1.25亿美元股票","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1},"content_text":"ADMA Biologics' stock surged 5.20% during intraday trading on Monday, following the company's announcement of a significant capital return initiative.The biopharmaceutical company revealed a planned $200 million share repurchase program for 2026, including a $125 million accelerated share repurchase agreement with JPMorgan. This initiative is part of the company's existing program authorizing up to $500 million in repurchases.ADMA's President and CEO Adam Grossman stated that the company views its common stock as \"meaningfully undervalued\" and represents \"the most compelling near-term capital deployment opportunity.\" The announcement reflects management's confidence in ADMA's strong financial position, durable free cash flow profile, and long-term growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125901366","isCrawlerRequest":true}